Sponsor:
Novartis Pharmaceuticals
Code:
NCT07635316
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Study ID
NCT07635316
Start date
Jun 12, 2026
Status verified date
Jul, 2026
Completion date
Feb 25, 2027
Anticipated
Primary completion date
Feb 25, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
4023 participants
Anticipated
Arms
Overall GEP-NET Cohort
1L Lutetium Lu 177 Dotatate Cohort
1L Capecitabine + Temozolomide (CAPTEM) Cohort
1L Cabozantinib Cohort
Lutetium Lu 177 Dotatate Cohort
CAPTEM Cohort
Cabozantinib Cohort
Primary outcome measure
Central contacts
Locations
Novartis
Recruiting
East Hanover, New Jersey, United States, 07936
Sponsor
Novartis Pharmaceuticals
Last update posted
Jul 6, 2026
Last verified
Jul, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-07-06.